Clinical trial
Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.
NCT03783416 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.
- Lead sponsor
- Queen Mary University of London
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 15, 2020
- Completion date
- July 31, 2027
- Enrollment
- 72 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary progressive multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis